Related Experiment Videos
Risk factors for hydrocortisone myopathy in acute severe asthma
1Chest Clinic, Medway Hospital, Gillingham, Kent, U.K.
Respiratory Medicine
|May 1, 1990
Summary
Four out of nine ventilated asthma patients developed hydrocortisone myopathy. This condition, characterized by severe weakness, occurred despite low daily doses, suggesting total cumulative dose is a key factor.
Area of Science:
- Critical Care Medicine
- Neurology
- Endocrinology
Background:
- Acute severe asthma necessitates mechanical ventilation and often intensive medical management.
- Corticosteroids, such as hydrocortisone, are commonly used in managing severe asthma exacerbations.
- Potential adverse effects of prolonged or high-dose corticosteroid therapy require ongoing investigation.
Observation:
- A significant proportion (4/9) of patients ventilated for acute severe asthma developed acute hydrocortisone myopathy.
- Affected patients exhibited severe generalized muscle weakness, with recovery over 1-6 weeks.
- Myopathy occurred even with daily hydrocortisone doses below 1.0 g/day.
Findings:
- The primary distinguishing factor between myopathic and unaffected patients was the total cumulative dose of hydrocortisone received.
- Myopathic patients had received total hydrocortisone doses exceeding 5.0 g (range 5.4-10.2 g).
- Unaffected patients received total hydrocortisone doses below 4.0 g (range 0.9-3.5 g).
Implications:
- Hydrocortisone myopathy can manifest even with seemingly low daily corticosteroid doses if the total cumulative dose is high.
- The findings suggest a potential link between neuromuscular blockade and the development of corticosteroid-induced myopathy.
- This highlights the importance of monitoring cumulative corticosteroid exposure in critically ill patients to prevent iatrogenic complications.